What TionLab Therapeutics does

TionLab Therapeutics is a South Korean pre-clinical-stage drug development company founded in 2021 that develops proprietary long-acting injectable drug delivery platforms. Its core technologies are the Depot Platform, which extends drug exposure duration from a single injection to enable monthly rather than weekly dosing (reducing injection frequency from 52 to 12 per year), and the Quject Sphere, a sister platform applied to obesity therapeutics. Additional formulation platforms target anti-diabetic and anti-obesity effects. The company operates from a research institute in Giheung-gu, Yongin-si and a head office in Gimhae-si, South Korea, with a small team of 1-10 employees under CEO Duck-soo Lim, and protects its technology through 10 patent applications across Korea, the US, Japan, Taiwan, and PCT.

The company's business model is platform licensing and co-development with pharmaceutical partners, generating revenue through licensing fees, development milestones, and potential royalties rather than direct product sales. Its lead program is a long-acting monthly semaglutide injectable developed jointly with Daewoong Pharmaceutical for the global obesity treatment market, for which IND was filed in April 2026 with clinical trials and commercial launch targeted within the year. Earlier commissioned research relationships with H Bio (biopharmaceutical eye drops), D-Bio (diabetes formulation), and D Pharmaceutical (clinical trial drug supply) demonstrate platform breadth across therapeutic areas including diabetes, obesity, cancer support, and ophthalmology.

TionLab's customer base is concentrated among Korean pharmaceutical partners, with Daewoong serving as both a strategic commercialization partner and an equity investor (KRW 1.25B participation in the 2024 KRW 5B round). The company has raised cumulative funding of approximately $3.75M USD from investors including E&Venture, IBK, AJU IB, Daewoong, Series Ventures, and Bluepoint Partners, supported by multiple Korean government programs (TIPS, KOTRA IKMP, First Penguin). It is not yet generating commercial revenue and remains in R&D and pre-clinical development.

Name

TionLab Therapeutics

Legal name

TionLab Therapeutics Co., Ltd.

Website

https://tionlabrx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

TionLab Therapeutics is a Korean pre-clinical biotech developing proprietary long-acting injectable drug delivery platforms (Depot and Quject Sphere) that reduce injection frequency, partnering with pharmaceutical companies like Daewoong to apply its technology to obesity, diabetes, and chronic disease treatments.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Long-acting injectables
• Drug delivery platforms
• Depot formulation technology
• Obesity therapeutics
• Pharmaceutical licensing

Headquarters

HQ city

Giheung

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing and Co-development: The company licenses its proprietary drug delivery platform technology to pharmaceutical partners and enters co-development arrangements for joint development of long-acting injectable drugs. Revenue is generated through licensing fees, milestone payments tied to development progress, and potentially royalty arrangements upon commercialization.
2. Strategic Partnerships and Joint Ventures: Revenue generated through strategic partnerships with pharmaceutical companies for joint development and commercialization of long-acting injectable treatments. Daewoong Pharmaceutical partnership represents a key commercial arrangement to develop and commercialize monthly semaglutide injectable for global obesity market.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

TionLab Therapeutics is a drug development company that designs and licenses proprietary long-acting injectable drug delivery platforms — the Depot Platform and Quject Sphere — which convert existing injectable drugs into sustained-release monthly formulations. The company's lead program is a monthly semaglutide injectable for obesity co-developed with Daewoong Pharmaceutical, reducing dosing from 52 weekly injections per year to 12 monthly injections.

Product overview

TionLab Therapeutics is an R&D-focused company developing proprietary long-acting injectable drug delivery technologies. The core offering consists of the Depot Platform and Quject Sphere technology, which enable sustained drug release from a single injection. The company applies these platforms primarily to obesity and diabetes treatments, with its lead product being a long-acting monthly semaglutide injectable developed in partnership with Daewoong Pharmaceutical, reducing dosing frequency from weekly (52 times/year) to monthly (12 times/year) injections.

Differentiator

Problem solved

Functional benefit

Products and services

• Depot Platform Proprietary drug delivery platform that prolongs drug exposure from a single injection, enabling existing injectable drugs to be reformulated as long-acting monthly doses. Licensed to pharmaceutical partners for co-development across obesity, diabetes, and other chronic indications.
• Quject Sphere Proprietary drug delivery technology specifically designed for obesity treatment applications, enabling sustained-release long-acting injectable formulations. Made available to pharmaceutical partners (notably Daewoong Pharmaceutical) for co-development of obesity therapeutics.
• Long-acting Monthly Semaglutide Injectable Long-acting injectable formulation of semaglutide co-developed with Daewoong Pharmaceutical for the global obesity treatment market, reducing injection frequency from 52 weekly injections per year to 12 monthly injections per year.

Quantifiable outcome

• Reduces injection frequency from 52 times per year to 12 times per year (77% reduction)
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Daewoong PharmaceuticalcoreStrategic or Co-development Partner · 8 May 2026Strategic partnership to jointly develop and commercialize a long-acting monthly semaglutide injectable for the global obesity treatment market. Combines TionLab's Quject Sphere drug delivery technology with Daewoong's CURE platform to reduce injection frequency from 52 to 12 times per year. Both companies filed for IND approval and plan to begin clinical trials with launch targeted within the year.
• Bluepoint PartnersminorOthers · 1 January 2021Bluepoint Partners partnered with company for TIPS (Tech Incubator Program for startup) support and investment attraction facilitation.
• H BiominorStrategic or Co-development Partner · 1 January 2021H Bio commissioned research on biopharmaceutical eye drops formulation conducted by company's research institute.
• D-BiominorStrategic or Co-development Partner · 1 January 2021Commissioned research on diabetes drug formulation conducted for D-Bio.
• D PharmaceuticalminorStrategic or Co-development Partner · 1 January 2021Signed MOU with D Pharmaceutical to produce proprietary depot drug clinical trial drugs.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Camurus: Swedish specialty pharma company developing the FluidCrystal technology platform for long-acting injectable depots, commercialized products include Buvidal (weekly/monthly buprenorphine) and others. Directly comparable sustained-release injectable platform play serving chronic disease markets.
• Adocia: French clinical-stage biotech developing innovative formulations of insulin and other diabetes/obesity peptides (e.g., BioChaperone platform) for prandial and sustained-release delivery. Closely matches TionLab's anti-diabetic and anti-obesity platform focus with similar technology-licensing approach.
• Intarcia Therapeutics: US biotech developing the ITCA 650 implantable osmotic pump that delivers exenatide continuously for 6-12 months for type 2 diabetes. Comparable mechanism of dramatically reducing dosing frequency for chronic metabolic disease via proprietary delivery technology.
• Halozyme Therapeutics: US-based drug delivery platform company whose ENHANZE technology enables long-acting injectable formulations of partner drugs via recombinant human hyaluronidase. Closely comparable business model of licensing a proprietary delivery technology to large pharma partners for royalty revenue.
• Pacira BioSciences: US specialty pharma commercializing long-acting injectable products including EXPAREL (multivesicular liposome-based bupivacaine) and ZILRETTA for osteoarthritis. Comparable long-acting injectable focus with proprietary formulation technology and pharma licensing model.

Broad incumbents

• Alkermes: Established specialty pharma with proprietary long-acting injectable technologies (ARISTADA, VIVITROL) for CNS disorders. Larger incumbent with overlapping long-acting depot technology, broader portfolio, and commercialization scale that TionLab aspires to reach.

Emerging players

• Serina Therapeutics: Clinical-stage biotech developing POZ-based polymer drug delivery technology for sustained-release CNS and other therapies. Earlier-stage but operates in the same long-acting injectable / sustained-release formulation space as TionLab's Depot platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TionLab Therapeutics